Chinook Therapeutics (NASDAQ:KDNY – Get Rating) announced its earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.13, Fidelity Earnings reports. Chinook Therapeutics had a negative return on equity of 26.45% and a negative net margin of 199.39%.
NASDAQ:KDNY traded up $0.86 during trading hours on Friday, hitting $13.97. The stock had a trading volume of 379,865 shares, compared to its average volume of 289,250. Chinook Therapeutics has a one year low of $10.48 and a one year high of $19.85. The business’s 50 day moving average is $14.82 and its 200-day moving average is $14.51.
In other Chinook Therapeutics news, insider Andrew James King sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, February 18th. The shares were sold at an average price of $13.00, for a total value of $32,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 23.38% of the stock is currently owned by corporate insiders.
Separately, Zacks Investment Research lowered Chinook Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 22nd.
Chinook Therapeutics Company Profile (Get Rating)
Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.
- Get a free copy of the StockNews.com research report on Chinook Therapeutics (KDNY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.